ACTRIMS 2024
Multiple Sclerosis News Today is providing coverage of the ninth annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024 Feb. 29-March 2 in West Palm Beach, Florida. The theme of this year’s conference is “Breaking Barriers in MS.”
People with relapsing forms of multiple sclerosis (MS) being treated with an infusion CD20 inhibitor such as Ocrevus (ocrelizumab) can safely transition to the more recent Briumvi (ublituximab-xiiy), which is given in shorter infusion times. That’s according to data from the ENHANCE Phase 3b clinical trial…
Recommended Posts
- New European patent covers all dosing regimens of experimental MS therapy
- My dysphagia from MS shows up during a difficult swallowing study
- Brain volume loss may not reflect disability in progressive MS
- Along with hardships, my MS diagnosis has been a journey of learning
- MS causing fewer deaths, less disability than in the past: Study